结核分枝杆菌潜伏感染中医辨证分型及治法方药专家共识

doi:10.19982/j.issn.1000-6621.20250421

摘要/Abstract

摘要：

开展结核分枝杆菌潜伏感染(latent tuberculosis infection, LTBI)的预防性治疗,是终结结核病流行策略的关键环节。然而,现代医学在结核病预防性治疗方面存在不良反应多、患者依从性差等挑战。相比之下,中医药基于治未病理念与疫病伏邪理论在LTBI预防性干预方面展现出独特优势,对实现LTBI精准诊疗至关重要。为明确LTBI中医辨证分型及相应治法方药,中国中医科学院中医临床基础医学研究所、浙江中医药大学附属丽水中医院、中国防痨协会与《中国防痨杂志》编辑委员会共同组织国内结核病防治多领域专家,包括中医理论、中医临床、流行病学及基础研究等专家,撰写了《结核分枝杆菌潜伏感染中医辨证分型及治法方药专家共识》(以下简称“共识”)。本共识系统阐述了LTBI的中医病因病机、辨证分型的核心要素,以及特殊人群的辨证要点。同时,明确了中医辨证分型的类别与关键特征,并针对各证型推荐了相应的治法与方药,旨在为LTBI的精准诊治提供参考依据。

关键词: 结核潜伏感染, 医学, 中国传统, 中医辨证分型, 伏邪, 总结性报告(主题)

Abstract:

The preventive treatment of latent tuberculosis infection (LTBI) is a key link in the strategy to end the epidemic of tuberculosis. However, the preventive treatment of tuberculosis in modern medicine has many challenges, such as many adverse reactions and poor patient compliance. In contrast, traditional Chinese medicine has shown unique advantages in the preventive intervention of LTBI based on the concept of preventing diseases before they occur and the theory of suppressing pathogenic diseases, which is crucial for achieving precise diagnosis and treatment of LTBI. In order to clarify the TCM syndrome differentiation and classification of LTBI and the corresponding treatment and prescription, Institute of Clinical Basic Medicine of Chinese Medicine of the Chinese Academy of Traditional Chinese Medicine, Lishui Hospital of Traditional Chinese Medicine of Zhejiang Province, Chinese Antituberculosis Association, and Editorial Board of Chinese Journal of Antituberculosis jointly organized domestic experts in various fields of tuberculosis, including experts in TCM theory, TCM clinic, epidemiology, and basic research, and wrote the Expert consensus on TCM syndrome differentiation, treatment principles, formulas, and herbs for latent tuberculosis infection (hereinafter referred to as the “Consensus”). This consensus system elaborates on the core elements of traditional Chinese medicine etiology and pathogenesis, syndrome differentiation and typing of LTBI, as well as the key points of syndrome differentiation for special populations. At the same time, the categories and key characteristics of TCM syndrome differentiation were clarified, and corresponding treatment methods and prescriptions were recommended for each syndrome type, aiming to provide reference for the precise diagnosis and treatment of LTBI.

Key words: Latent tuberculosis infection, Medicine, Chinese traditional, TCM syndrome differentiation, Latent pathogen, Consensus development conferences as topic

中图分类号:

中国中医科学院中医临床基础医学研究所, 浙江中医药大学附属丽水中医院, 中国防痨协会, 《中国防痨杂志》编辑委员会. 结核分枝杆菌潜伏感染中医辨证分型及治法方药专家共识[J]. 中国防痨杂志, 2026, 48(1): 1-8. doi: 10.19982/j.issn.1000-6621.20250421

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences , Lishui Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University , Chinese Antituberculosis Association , Editorial Board of the Chinese Journal of Antituberculosis . Expert consensus on TCM syndrome differentiation, treatment principles, formulas, and herbs for latent tuberculosis infection[J]. Chinese Journal of Antituberculosis, 2026, 48(1): 1-8. doi: 10.19982/j.issn.1000-6621.20250421

参考文献 67

[1]	胡鑫洋, 高静韬. 世界卫生组织《2024年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5 (6): 500-504. doi:10.19983/j.issn.2096-8493.2024164.
[2]	World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization, 2015.
[3]	World Health Organization. WHO calls for urgent action to end TB: Editors notes:About the UN High-level Meeting on TB The United Nations General Assembly High-level. Geneva: World Health Organization, 2018.
[4]	World Health Organization. Update of WHO guidelines on the management of latent TB infection. Geneva: World Health Organization, 2019.
[5]	Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med, 2016, 13(10): e1002152. doi:10.1371/journal.pmed.1002152.
[6]	高磊, 张慧, 胡茂桂, 等. 基于多中心调查数据和空间统计模型的全国结核分枝杆菌潜伏感染率估算. 中国防痨杂志, 2022, 44(1): 54-59. doi:10.19982/j.issn.1000-6621.20210661.
[7]	Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol, 1974, 99(2): 131-138. doi:10.1093/oxfordjournals.aje.a121593. pmid: 4810628
[8]	Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect, 1997, 119(2): 183-201. doi:10.1017/s0950268897007917. pmid: 9363017
[9]	郭同磊, 辛赫男, 高磊. 《世界卫生组织结核病整合指南模块1: 结核病预防性治疗》解读. 中国防痨杂志, 2023, 45(8): 723-727. doi:10.19982/j.issn.1000-6621.20230199.
[10]	马艳, 陆伟, 高磊, 等. 终止结核病流行须加强结核分枝杆菌潜伏感染高危人群筛查和预防性治疗的管理. 中国防痨杂志, 2022, 44(3): 209-214. doi:10.19982/j.issn.1000-6621.20220008.
[11]	马艳, 陆伟, 成诗明. 结核分枝杆菌潜伏感染现状及防控对策. 解放军医学杂志, 2023, 48(6): 634-642. doi:10.11855/j.issn.0577-7402.2023.06.0634.
[12]	马艳, 成诗明. 加速我国结核潜伏感染筛查与预防性治疗的建议. 实用医学杂志, 2023, 39(11): 1335-1340. doi:10.3969/j.issn.1006-5725.2023.11.003.
[13]	中国疾病预防控制中心结核病预防控制中心. 中国结核病防治工作技术指南. 北京: 人民卫生出版社, 2021: 5.
[14]	赵雁林, 陆伟, 沙巍. 结核潜伏感染人群预防性治疗手册. 北京: 人民卫生出版社, 2022: 4.
[15]	Zenner D, Beer N, Harris RJ, et al. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis. Ann Intern Med, 2017, 167(4): 248-255. doi:10.7326/M17-0609. pmid: 28761946
[16]	Gao L, Zhang H, Xin H, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J, 2018, 52(6): 1801470. doi:10.1183/13993003.01470-2018.
[17]	Xin H, Cao X, Zhang H, et al. Protective efficacy of 6-week regimen for latent tuberculosis infection treatment in rural China: 5-year follow-up of a randomised controlled trial. Eur Respir J, 2022, 60(1): 2102359. doi:10.1183/13993003.02359-2021.
[18]	Ruan QL, Huang XT, Yang QL, et al. Efficacy and safety of weekly rifapentine and isoniazid for tuberculosis prevention in Chinese silicosis patients: a randomized controlled trial. Clin Microbiol Infect, 2021, 27(4): 576-582. doi:10.1016/j.cmi.2020.06.008.
[19]	翁丽霞, 王勇. 学校涂阳肺结核密切接触者筛查及预防性服药效果分析. 国际流行病学传染病学杂志, 2014, 41(4): 258-260. doi:10.3760/cma.issn.1673-4149.2014.04.011.
[20]	Xin H, Zhang H, Yang S, et al. 5-Year Follow-up of Active Tuberculosis Development From Latent Infection in Rural China. Clin Infect Dis, 2020, 70(5): 947-950. doi:10.1093/cid/ciz581. pmid: 31253988
[21]	祖之鹏, 陈海婷, 陈园园, 等. 耐多药结核病患者密切接触者抗结核预防性治疗研究进展. 中国防痨杂志, 2025, 47(11): 1528-1534. doi:10.19982/j.issn.1000-6621.20250299.
[22]	Swindells S, Ramchandani R, Gupta A, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med, 2019, 380(11): 1001-1011. doi:10.1056/NEJMoa1806808.
[23]	中国防痨协会. 高危人群结核分枝杆菌潜伏感染检测及预防性治疗专家共识. 中国防痨杂志, 2021, 43(9): 874-878. doi:10.3969/j.issn.1000-6621.2021.09.004.
[24]	师晓晶, 郭建花, 王鑫, 等. 石家庄市结核分枝杆菌潜伏感染者预防性治疗接受度及影响因素研究. 中国防痨杂志, 2025, 47(6): 746-752. doi:10.19982/j.issn.1000-6621.20240591.
[25]	佟琳, 马艳, 范逸品, 等. 基于文献的清肺排毒汤组方治疫应用规律探讨. 中医杂志, 2021, 62(21): 1877-1881. doi:10.13288/j.11-2166/r.2021.21.007.
[26]	孙巧思, 胡镜清, 刘理想. 论中医学疫病防治特色. 中国中医基础医学杂志, 2021, 27(1): 42-45, 49.
[27]	曹玉清, 尚希钰, 熊一白, 等. 青蒿素研发的成功经验对结核病防治的借鉴与启示. 结核与肺部疾病杂志, 2023, 4(6): 442-448. doi:10.19983/j.issn.2096-8493.20230089.
[28]	Xiong Y, Bao L, Ma Y, et al. Wen-Yi and Chinese medicine: Why we need to pay attention? Sci Bull (Beijing), 2024, 69(11): 1617-1622. doi:10.1016/j.scib.2024.03.059.
[29]	朱凌凌, 段逸山, 高驰, 等. 肺痨病名源流考. 中华中医药杂志, 2018, 33(7): 2994-2999.
[30]	彭博文, 李董男. 清代医家“扶正避邪”防疫思想和方法探析. 中国中医基础医学杂志, 2024, 30(6): 924-928. doi:10.19945/j.cnki.issn.1006-3250.2024.06.001.
[31]	马希骏, 杜沁圆, 张义敏, 等. 《温疫论》疫病论治中补法运用探析. 北京中医药大学学报, 2023, 46(3): 331-335. doi:10.3969/j.issn.1006-2157.2023.03.008.
[32]	严家凤. 中医“正气存内,邪不可干”的防疫思维释义. 医学与哲学, 2022, 43(1): 63-66. doi:10.12014/j.issn.1002-0772.2022.01.14.
[33]	王国为, 杨威, 黄毅, 等. 《素问遗篇》疫病防治策略研究. 亚太传统医药, 2020, 16(10): 7-10. doi:10.11954/ytctyy.202010003.
[34]	张闯, 张夏梦, 夏雨果, 等. 基于“未病先防,既病防变,瘥后防复”理论探讨疫病的中医防治. 西部中医药, 2021, 34(9): 1-4. doi:10.12174/j.issn.1004-6852.2021.09.01.
[35]	徐梦丹, 杨长福, 林昶, 等. 从“未病先防”与“既病防变”探讨新冠肺炎的中医防治. 贵州中医药大学学报, 2020, 42(2): 7-10, 15. doi:10.16588/j.cnki.issn1002-1108.2020.02.002.
[36]	蔡华珠, 洪菲萍, 纪立金, 等. “正气存内, 邪不可干”的内涵及运用探析. 中华中医药杂志, 2015, 30(4): 987-989.
[37]	丰银平, 张尊敬, 蔡秋杰, 等. 基于伏邪理论探讨结核分枝杆菌潜伏感染辨治思路. 中国防痨杂志, 2025, 47(10): 1249-1253. doi:10.19982/j.issn.1000-6621.20250327.
[38]	穆婷婷, 张旭阳, 马艳, 等. 基于《理虚元鉴》“三本二统”治虚理论论治肺痨. 中国防痨杂志, 2025, 47(11): 1522-1527. doi:10.19982/j.issn.1000-6621.20250329.
[39]	邱磊, 张少言, 郭晓燕, 等. 化疗方案加芩部丹片治疗复治涂阳肺结核患者的临床价值. 中国防痨杂志, 2020, 42(2): 108-114. doi:10.3969/j.issn.1000-6621.2020.02.006.
[40]	费婉婉, 鹿振辉, 黄星, 等. 基于“肺与大肠相表里”探讨肠道菌群与肺结核关系的研究进展. 中国防痨杂志, 2022, 44(5): 500-504. doi:10.19982/j.issn.1000-6621.20210582.
[41]	庄丽, 马子风, 蒋雨薇, 等. 基于网络药理学的中药组方“芩部丹”治疗肺结核作用机制研究. 中国防痨杂志, 2022, 44(3): 273-283. doi:10.19982/j.issn.1000-6621.20210572.
[42]	彭草云, 阮月芳, 钱惠江. 初治肺结核患者体质与T淋巴细胞亚群关系的研究. 中国现代医生, 2023, 61(21): 1-4, 14. doi:10.3969/j.issn.1673-9701.2023.21.001.
[43]	郭净, 刘忠达, 张尊敬, 等. 老年肺结核患者中医药诊治研究进展. 中国防痨杂志, 2024, 46(11): 1406-1409. doi:10.19982/j.issn.1000-6621.20240192.
[44]	丘海先. 中医药治疗肺结核研究进展. 亚太传统医药, 2015, 11(12): 43-44. doi:10.11954/ytctyy.201512019.
[45]	傅景华, 陈心智. 黄帝内经素问. 北京: 中医古籍出版社, 1997: 2.
[46]	赵明芬, 安冬青, 汪建萍. 试论伏邪理论的源流及发展. 中医杂志, 2016, 57(3): 189-192. doi:10.13288/j.11-2166/r.2016.03.003.
[47]	吴文军, 刘西洋, 冯全生, 等. 试论伏气学说之“伏”. 中华中医药杂志, 2021, 36(10): 5804-5806.
[48]	杨映映, 田传玺, 赵林华. 论伏邪致病的因机证治. 长春中医药大学学报, 2024, 40(11): 1189-1191. doi:10.13463/j.cnki.cczyy.2024.11.003.
[49]	戴志澄, 肖东楼, 万利亚. 中国防痨史. 北京: 人民卫生出版社, 2013.
[50]	刘剑君, 王黎霞. 现代结核病学. 北京: 人民卫生出版社, 2022.
[51]	梁晨, 唐神结, 林明贵. 结核病综合治疗研究进展. 结核与肺部疾病杂志, 2024, 5(1): 70-80. doi:10.19983/j.issn.2096-8493.20230112.
[52]	付子珊, 杨宇峰, 石岩. 肺痨病因病机理论框架研究. 河北中医, 2021, 43(5): 856-859. doi:10.3969/j.issn.1002-2619.2021.05.033.
[53]	Gao L, Lu W, Bai L, et al. Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis, 2015, 15(3): 310-319. doi:10.1016/S1473-3099(14)71085-0. pmid: 25681063
[54]	钟涛, 詹广兴, 范玉铮, 等. 深圳市南山区高危人群结核菌潜伏感染情况及影响因素. 中国热带医学, 2020, 20(8): 702-709, 716. doi:10.13604/j.cnki.46-1064/r.2020.08.03.
[55]	李晓雪, 肖筱, 徐春华, 等. 活动性结核病患者密切接触者结核分枝杆菌潜伏感染率的Meta分析. 结核与肺部疾病杂志, 2024, 5(5): 404-414. doi:10.19983/j.issn.2096-8493.2024128.
[56]	Zhu Z, Shen W, Hu J, et al. Risk factors for latent tuberculosis infection clustering among the elderly: a population-based cross-sectional study in Eastern China. BMC Infect Dis, 2025, 25(1):368. doi: 10.1186/s12879-025-10743-7.
[57]	宋慧荣, 倪诚, 王济, 等. 老年生理与体质特点辨析及其临床意义. 天津中医药, 2021, 38(9): 1089-1092. doi:10.11656/j.issn.1672-1519.2021.09.01.
[58]	黄小原, 翟双庆. 论膜原为周身之间隙. 中医杂志, 2023, 64(4): 422-424. doi:10.13288/j.11-2166/r.2023.04.019.
[59]	马雪颜, 秦雪颖, 谷晓红. 膜系理论探讨. 北京中医药大学学报, 2023, 46(7): 931-936. doi:10.3969/j.issn.1006-2157.2023.07.007.
[60]	杨晨曦, 鲁明源. 三焦与膜原内涵及其关系辨析. 中华中医药杂志, 2022, 37(10): 5703-5707.
[61]	张永前. 中医体质学的中医哲学“辨证法”内涵探讨. 中医研究, 2014, 27(12): 7-8. doi:10.3969/j.issn.1001-6910.2014.12.04.
[62]	朱燕波. 中医体质分类判定与兼夹体质的综合评价. 中华中医药杂志, 2012, 27(1): 37-39.
[63]	冯立慧, 李燕秋, 林婧, 等. HIV/AIDS患者ART过程中血红蛋白水平对免疫学失败、预后的影响[J/OL]. 中国皮肤性病学杂志: 1-17 [2025-11-07]. https://doi.org/10.13735/j.cjdv.1001-7089.202501001.[网络预发表].
[64]	夏露, 卢水华, 刘平. 中药对结核病免疫调控机制的研究进展. 中国防痨杂志, 2020, 42 (2):168-172. doi:10.3969/j.issn.1000-6621.2020.02.016.
[65]	洪伟玲, 王潇, 施静怡, 等. 抗结核中药的作用机制研究进展. 中医药学报, 2024, 52(4): 91-98. doi:10.19664/j.cnki.1002-2392.240081.
[66]	李佳颖, 王晓婧, 尚家起, 等. 抗分枝杆菌植物天然产物研究进展. 中国抗生素杂志, 2022, 47(12): 1225-1231. doi:10.3969/j.issn.1001-8689.2022.12.001.
[67]	中华人民共和国国家卫生和计划生育委员会. WS 288—2017肺结核诊断. 结核与肺部疾病杂志, 2024, 5(4):376-378. doi:10.19983/j.issn.2096-8493.2024022.